CERSCI THERAPEUTICS INCORPORATED
Small molecule compounds that scavenge or catalyze decomposition of peroxynitrite to treat migraine
- Sector
- Biotech
- Headquarters
- DALLAS, TX
- Founded
- 2019
- Latest Form D
- $8M, Oct 2019
- Total capital
- $12.4M
- Federal grants
- $4.4M
- 7 awards · 2017–2018
- Rank in peer group#507 of 514
- Private capital raised
- $8M
- 1 Form D · last Oct 2019
- 85 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 16 pending · first 2020
- Rank in peer group#142 of 514
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$8M
- Federal grantHealth and Human S · Phase I · Non-Metal PN Scavenger/Decomposition Catalysts for Treatment of Migraine$222K
- Federal grantHealth and Human S · Phase I · Non-Metal PN Scavenger/Decomposition Catalysts for Treatment of Migraine$222K
- Federal grantHealth and Human S · Phase II · Orally-Bioavailable Peroxynitrite Decomposition Catalyst Targeting Post-Surgical Pain$1.1M
- Federal grantHealth and Human S · Phase II · Orally-Bioavailable Peroxynitrite Decomposition Catalyst Targeting Post-Surgical Pain$1.7M
- Federal grantHealth and Human S · Phase II · Orally-Bioavailable Peroxynitrite Decomposition Catalyst Targeting Post-Surgical Pain$658K
- Federal grantHealth and Human S · Phase I · Novel AMPK Activators for the Treatment of Neuropathic Pain$225K
Show 1 earlier federal award
- Federal grantHealth and Human S · Phase I · Novel AMPK Activators for the Treatment of Neuropathic Pain$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
32months
from CERSCI THERAPEUTICS INCORPORATED’s first federal award to its first private round.
- First federal award · Jan 2017
- Health and Human S · $225K
- First Form D · Oct 2019
- $8M · 1st Form D
- Awards before first raise
- 7 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#142 · top 28%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Dennis RobbinsResearcherDirectorLinked by 1 patent
- Scott DaxResearcherDirectorLinked by $2M in grants as PI
- Brent DuncanDirectorNamed in SEC Form D filings
- David GenecovDirectorNamed in SEC Form D filings
- David Hitt IIDirectorNamed in SEC Form D filings
- John D. Harkey, Jr.DirectorNamed in SEC Form D filings
Show all 10 people
- Lucas RodriguezExecutive Officer, DirectorNamed in SEC Form D filings
- Pat ConfaloneDirectorNamed in SEC Form D filings
- Perry MolinoffDirectorNamed in SEC Form D filings
- Tyler BrousDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 18- GrantedCompounds for Pain Treatment, Compositions Comprising Same, and Methods of Using SameUSPTOUS 10,844,054
- PendingMethods Of Treating Pain With A Thiazoline Anti-hyperalgesicUSPTOApplication 16886074
- PendingMethods Of Treating Pain With A Thiazoline Anti-hyperalgesicUSPTOApplication 16720819
Show all 18 patent records
- Compounds for Pain Treatment, Compositions Comprising Same, and Methods of Using SameNov 24, 2020 · US 10,844,054Granted
- Methods Of Treating Pain With A Thiazoline Anti-hyperalgesicSep 17, 2020 · Application 16886074Pending
- Methods Of Treating Pain With A Thiazoline Anti-hyperalgesicAug 6, 2020 · Application 16720819Pending
- Methods Of Treating Post-surgical Pain With A Thiazoline Anti-hyperalgesic AgentAug 6, 2020 · Application 16446307Pending
- Methods Of Treating Diabetic Neuropathy With A Thiazoline Anti-hyperalgesic AgentAug 6, 2020 · Application 16654405Pending
- Ampk Agonist Topical Medication For The Treatment Of Certain Specific Medical Conditions, Methods Of Use Thereof And Wound Dressing Employing The SameJun 30, 2020 · US 10,695,287Granted
- Compounds For Pain Treatment, Compositions Comprising Same, And Methods Of Using SameApplication PCTUS2019033140Pending
- Manufacturing Methods And Polymorphs Of A Thiazoline Anti-hyperalgesic AgentApplication 62846096Pending
- Methods Of Treating Pain With A Thiazolidine Anti-hyperalgesicApplication 62800232Pending
- Compounds For Pain Treatment, Compositions Comprising Same, And Methods Of Using SameApplication 62677496Pending
- Ampk Agonist Topical Medication For The Treatment Of Certain Specific Medical Conditions, Methods Of Use Thereof And Wound Dressing Employing The SameApplication 15354372Pending
- Analgesic Compounds, Compositions, And Uses ThereofApplication 17228427Pending
- Ampk Agonist Topical Medication For The Treatment Of Certain Specific Medical Conditions, Methods Of Use Thereof And Wound Dressing Employing The SameApplication 62256402Pending
- Manufacturing Methods And Polymorphs Of A Thiazoline Anti-hyperalgesic AgentApplication PCTUS2020021883Pending
- Methods Of Treating Pain With A Thiazoline Anti-hyperalgesicApplication PCTUS2019067454Pending
- Methods Of Treating Diabetic Neuropathy With A Thiazoline Anti-hyperalgesic AgentApplication PCTUS2019056489Pending
- Methods Of Treating Diabetic Neuropathy With A Thiazoline Anti-hyperalgesic AgentApplication 62882372Pending
- Methods Of Treating Post-surgical Pain With A Thiazoline Anti-hyperalgesic AgentApplication PCTUS2019038028Pending
Related companies, and why
- NUSIRT SCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- Stem Biotech LLCSimilar federal contract value in Biotech · null in contracts
- EPIVAX, INC.Similar federal contract value in Biotech · null in contracts
- BeneFix, Inc.Similar federal contract value in Biotech · null in contracts
- ARMONICA TECHNOLOGIES, INC.Similar federal contract value in Biotech · null in contracts
- ESCAZYME BIOCHEMICALS, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .